Eiger BioPharmaceuticals Inc
OTC:EIGRQ

Watchlist Manager
Eiger BioPharmaceuticals Inc Logo
Eiger BioPharmaceuticals Inc
OTC:EIGRQ
Watchlist
Price: 8.5 USD Market Closed
Market Cap: $12.6m

Operating Margin

-455.1%
Current
Improving
by 132.6%
vs 3-y average of -587.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-455.1%
=
Operating Income
$-71.8m
/
Revenue
$15.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-455.1%
=
Operating Income
$-71.8m
/
Revenue
$15.8m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Eiger BioPharmaceuticals Inc
OTC:EIGRQ
12.6m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.9B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD
Loading...

Market Distribution

Lower than 91% of companies in the United States of America
Percentile
9th
Based on 14 112 companies
9th percentile
-455.1%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Eiger BioPharmaceuticals Inc
Glance View

Market Cap
12.6m USD
Industry
Biotechnology

Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. The company is headquartered in Palo Alto, California and currently employs 27 full-time employees. The company went IPO on 2014-01-30. The firm is focused on the development of therapies to treat and cure Hepatitis Delta Virus (HDV), the severe form of viral hepatitis, and other serious diseases. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Post-Bariatric Hypoglycemia (PBH) and Avexitide in Congenital Hyperinsulinism (CHI). Lambda is a late-stage, type III, interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. Avexitide is a peptide, which is developing as a treatment for congenital hyperinsulinism (HI). The company is also developing lambda as an out-patient treatment for patients with mild and moderate COVID-19. The firm is also developing Avexitide as a treatment for post-bariatric hypoglycemia (PBH).

EIGRQ Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-455.1%
=
Operating Income
$-71.8m
/
Revenue
$15.8m
What is Eiger BioPharmaceuticals Inc's current Operating Margin?

The current Operating Margin for Eiger BioPharmaceuticals Inc is -455.1%, which is above its 3-year median of -587.7%.

How has Operating Margin changed over time?

Over the last 3 years, Eiger BioPharmaceuticals Inc’s Operating Margin has increased from -1 732.6% to -455.1%. During this period, it reached a low of -1 732.6% on Mar 31, 2021 and a high of -455.1% on Jan 31, 2024.

Back to Top